Please login to the form below

Not currently logged in
Email:
Password:

Acacia Pharma

This page shows the latest Acacia Pharma news and features for those working in and with pharma, biotech and healthcare.

Acacia finally gets FDA okay for first product Barhemsys

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... sedation. It licensed the drug from Cosmo Pharma in a deal that also

Latest news

  • Acacia eyes February FDA verdict for refiled nausea drug Barhemsys Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

    Back on track after being turned down twice. Acacia Pharma’s experimental drug for post-operative nausea and vomiting (PONV) looks back on track, after being turned down twice by the ... Acacia’s Euronext-listed shares rose almost 3% on news of the

  • UK biotech booms in 2018, despite Brexit worries UK biotech booms in 2018, despite Brexit worries

    There were just five initial public offering (IPOs) in the year, raising £432m, with another £658m coming from follow-on public financings, including a £273m round from GW Pharma. ... 2018’s UK IPOs came fromSensyne Health, Acacia Pharma and

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...